Abstract
Background: The chemokine CXCL10 is a potent chemoattractant for activated lymphocytes and dendritic cells and mediates vascular injury by inducing intimal hyperplasia and inhibition of endothelial cell growth. Neutralisation of CXCL10 prolongs allograft survival and transplant knock-out models have shown that this chemokine is required for the initiation and development of graft failure due to both acute and chronic rejection. In the present study, we investigated whether pre-transplant CXCL10 serum levels may predict the recipient risk of graft rejection and transplant failure. Methods: Pre-transplant sera of 299 cadaver kidney graft recipients were tested retrospectively for serum CXCL10 levels by a quantitative sandwich immunoassay. Results: Kidney graft recipients with normally functioning grafts showed higher pre-transplant CXCL10 serum levels than healthy controls, but significantly lower than patients who experienced graft failure (133.47±119.6 vs. 182.8±155.01 pg/ml; p
Original language | English |
---|---|
Pages (from-to) | 91-96 |
Number of pages | 6 |
Journal | Transplantationsmedizin: Organ der Deutschen Transplantationsgesellschaft |
Volume | 15 |
Issue number | 2 |
Publication status | Published - 2003 |
Keywords
- Allograft failure
- Allograft rejection
- Chemokines
- IP-10
- Renal transplantation
ASJC Scopus subject areas
- Transplantation
- Immunology and Allergy